BTN1A1 as A Potential Drug Target for Neurological Disorders (G696)

Target Name: BTN1A1

NCBI ID: G696

BTN1A1

BTN1A1 as A Potential Drug Target for Neurological Disorders

BTN1A1, also known as BTN1A1-G1, is a protein that is expressed in the brain and is known for its role in the regulation of cell survival and proliferation. The BTN1A1 gene has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression.

BTN1A1 is a transmembrane protein that is expressed in the brain and is involved in the regulation of various cellular processes, including cell survival, migration, and survival signaling. It is a key regulator of the microtubule network, which is a network of filaments that organize and regulate the movement of cells in the brain.

Studies have shown that BTN1A1 is involved in the regulation of cell survival and proliferation in various brain regions, including the prefrontal cortex, a region of the brain that is involved in executive function and decision-making. Studies have also shown that BTN1A1 is involved in the regulation of neurotransmitter release from neurons, which is important for the proper functioning of the brain.

In addition to its role in cell survival and proliferation, BTN1A1 is also involved in the regulation of cellular signaling pathways that are important for brain development and plasticity. For example, studies have shown that BTN1A1 is involved in the regulation of the Wnt signaling pathway, which is important for the development and maintenance of the brain.

As a potential drug target, BTN1A1 is an attractive target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. These disorders are characterized by the progressive loss of brain cells and the formation of aggregates of toxic proteins, which can cause the symptoms associated with these disorders.

In the case of Alzheimer's disease, the progressive loss of brain cells and the formation of aggregates of beta-amyloid protein are thought to be the underlying causes of the disease. BTN1A1 has been shown to be involved in the regulation of beta-amyloid protein synthesis and storage, which may be a potential target for the treatment of Alzheimer's disease.

In the case of Parkinson's disease, the progressive loss of brain cells and the formation of aggregates of alpha-synuclein protein are thought to be the underlying causes of the disease. BTN1A1 has been shown to be involved in the regulation of alpha-synuclein protein synthesis and storage, which may be a potential target for the treatment of Parkinson's disease.

In the case of depression, the progressive loss of brain cells and the formation of aggregates of serotonin and dopamine are thought to be the underlying causes of the disease. BTN1A1 has been shown to be involved in the regulation of serotonin and dopamine signaling pathways, which may be a potential target for the treatment of depression.

In conclusion, BTN1A1 is a protein that is expressed in the brain and is involved in the regulation of various cellular processes that are important for brain development and plasticity. The BTN1A1 gene has been identified as a potential drug target for the treatment of various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. Further research is needed to fully understand the role of BTN1A1 in these disorders and to develop effective treatments.

Protein Name: Butyrophilin Subfamily 1 Member A1

Functions: May function in the secretion of milk-fat droplets. May act as a specific membrane-associated receptor for the association of cytoplasmic droplets with the apical plasma membrane (By similarity). Inhibits the proliferation of CD4 and CD8 T-cells activated by anti-CD3 antibodies, T-cell metabolism and IL2 and IFNG secretion (By similarity)

The "BTN1A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTN1A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets